Pfizer, Gilead and others seek clarifications on trial designs outlined in FDA's UC and Crohn's draft guidance

Multiple Big Pharma companies sought tweaks from the FDA on draft guidance related to the development of new drugs for ulcerative colitis and Crohn’s disease. Those two indications are key therapeutic areas for several of the major pharma players.